Search Results
Your search for The,The matches 35174 pages
Showing 7701 - 7750(My) German Hodgkin Story
Nearly 200 years ago, Thomas Hodgkin for the first time described a peculiar disease with undulating fever, enlarged lymph nodes, and a big spleen. Its nature was obscure. It was a fatal illness, affecting mainly young adults and children. In 1865, Samuel Wilks named this illness Hodgkin’s...
PARP Inhibitor Plus Abiraterone Benefits Subgroups of Patients With Metastatic Castration-Resistant Prostate Cancer
The combination of the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib plus abiraterone acetate and prednisone as first-line therapy significantly improved radiographic progression-free survival vs abiraterone and placebo alone in men with metastatic castration-resistant prostate cancer...
Researchers Identify Biomarkers That May Help to Predict Response to Immunotherapy for Melanoma
Melanoma is often curable when detected and treated in its early stages. However, the disease can rapidly spread to other organs in the body and become deadly. Immune checkpoint inhibitors have transformed the treatment of certain cancers, including melanoma, and improved patient care. But despite...
Understanding How LGBTQI+ Cancer Survivors Experience Cancer Care
Members of the lesbian, gay, bisexual, transgender, and queer/questioning, intersexed (LGBTQI+) community face numerous challenges and barriers when accessing the health-care system in the United States, including cancer care; as a result, they may be at greater risk for developing cancer and...
Does MRI-Guided Radiotherapy Reduce Treatment-Related Side Effects in Patients With Prostate Cancer?
An interim analysis of an ongoing phase III study indicated that using magnetic resonance imaging (MRI) to guide stereotactic body radiotherapy for patients with prostate cancer reduced side effects associated with the treatment. The findings were presented at the 2022 ASCO Genitourinary Cancers...
Expert Point of View: George D. Demetri, MD, FASCO
ASCO invited comments on the INTRIGUE study from George D. Demetri, MD, FASCO, Professor of Medicine at Harvard Medical School and Director of the Center for Sarcoma and Bone Oncology, Senior Vice President for Experimental Therapeutics, and Quick Family Chair in Medical Oncology at Dana-Farber...
Similar Efficacy but Better Tolerability for Ripretinib vs Sunitinib in Second-Line GIST Therapy
In the INTRIGUE trial, reported during the January 2022 session of the virtual ASCO Plenary Series, the tyrosine kinase inhibitor ripretinib was not superior to sunitinib in the second-line treatment of patients with advanced gastrointestinal stromal tumors (GIST) but was better tolerated.1...
Copanlisib in Patients With PIK3CA-Mutated Tumors
In a phase II trial reported in the Journal of Clinical Oncology, Damodaran et al found that the phosphoinositide 3-kinase (PI3K) inhibitor copanlisib exhibited activity in patients who have tumors with PIK3CA mutations. The study is a subprotocol (Z1F) of the NCI-MATCH ECOG-ACRIN trial (EAY131), a ...
Expert Point of View: Jane N. Winter, MD
Jane N. Winter, MD, moderator of the press conference on late-breaking abstracts at the 2021 American Society of Hematology (ASH) Annual Meeting & Exhibition, commented on the BELINDA study in the context of two investigations that had been previously reported at the same meeting. These two...
Matthew R. Zibelman, MD, on Renal Cell Carcinoma: New Results on Combination of Nivolumab and Axitinib
Matthew R. Zibelman, MD, of Fox Chase Cancer Center, discusses phase I/II results from a study of treatment-naive patients with advanced renal cell carcinoma who received a combination of the immunotherapy (IO) nivolumab and the tyrosine kinase inhibitor (TKI) axitinib. The findings suggest that...
BELINDA: CAR T-Cell Therapy Fails to Improve Outcomes in Aggressive Non-Hodgkin Lymphoma
The autologous chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel failed to improve event-free survival vs standard-of-care treatment strategies in patients with aggressive, relapsed or refractory non-Hodgkin lymphoma (NHL), according to the results of the phase III BELINDA trial,...
Expert Point of View: Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, of Sylvester Comprehensive Cancer Center, University of Miami, called the results of the AGILE study “very promising.” He moderated a press briefing that featured the abstract at the American Society of Hematology (ASH) Annual Meeting & Exposition. “Patients with the...
AGILE: Addition of Ivosidenib to Azacitidine Triples Median Overall Survival in Difficult-to-Treat AML Population
In patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation who were ineligible for intensive chemotherapy, the addition of the IDH1 inhibitor ivosidenib to azacitidine significantly improved survival vs azacitidine alone, according to data presented at the 2021 American...
Study Evaluates Effectiveness of Existing Risk Stratification System for Hepatoblastoma
A new study published by Zhou et al in JAMA Network Open independently verified the value of a system that assesses hepatoblastoma risk in children. The researchers also discovered the potential for tumor histology to predict a patient’s hepatoblastoma prognosis. Hepatoblastoma is a rare childhood ...
Expert Point of View: Joshua Brody, MD
Joshua Brody, MD, Director of the CLL/Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai, New York, who was not involved in these trials, commented: “CLL is an extremely prevalent disease affecting nearly 200,000 patients in the United States. Most patient do not require...
Fixed-Duration Venetoclax Plus Ibrutinib Achieves Deep and Durable MRD Remissions in CLL
Two different trials presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition found that fixed-duration treatment with ibrutinib and venetoclax achieved deep and sustained undetectable measurable residual disease (MRD) status when used as first-line therapy for...
Study Examines Predictive Biomarker for Bladder Cancer Survival
Long-term survival data from the first prospective, randomized biomarker validation trial in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery are being reported at the 2022 ASCO Genitourinary Cancers Symposium by Thomas W. Flaig, MD, and...
Expert Point of View: Susan M. O’Brien, MD
The GAIA trial raises some important points, according to Susan M. O’Brien, MD, Associate Director for Clinical Research at the UCI Chao Family Comprehensive Cancer Center in Irvine, California. Dr. O’Brien co-moderated the session where Dr. Eichhorst presented study results. “The CLL14 trial...
Improved Outcomes With Time-Limited Venetoclax Combinations vs Chemoimmunotherapy in Fit Patients with CLL
Administering time-limited regimens that were combinations of venetoclax plus obinutuzumab or venetoclax plus obinutuzumab and ibrutinib was superior to chemoimmunotherapy in achieving undetectable measurable residual disease in the peripheral blood at month 15 in fit patients with chronic...
Expert Point of View: Laura C. Michaelis, MD
The moderator of the press briefing on COVID-19 in patients with blood disorders, held during the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, was Laura C. Michaelis, MD, a clinician and clinical researcher at the Medical College of Wisconsin, Milwaukee. Dr. Michaelis...
Aggressive Supportive Treatment for COVID-19 May Be Needed in Patients With Hematologic Cancers
New research underscores the need for aggressive support of patients hospitalized with blood cancer and COVID-19, according to data presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition. Two studies of one of the largest data sets of patients with blood cancer...
Expert Point of View: Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, Professor of Medicine and Chief of the Division of Hematology, Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine, said the “fascinating” findings of the study reported by Bouzid et al make it worthy of an ASH Plenary Session...
Neoadjuvant Enfortumab Vedotin-ejfv in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer
The antibody-drug conjugate enfortumab vedotin-ejfv is effective in patients with muscle-invasive bladder cancer who are not eligible for cisplatin chemotherapy, according to data from cohort H of the phase IB/II EV-103 clinical trial being presented at the 2022 ASCO Genitourinary Cancers Symposium ...
CHIP Mutations Associated With Lower Risk of Alzheimer’s Disease
The presence of clonal hematopoiesis of indeterminate potential, or CHIP, increases the risk of developing a myeloid malignancy and also cardiovascular disease—which are well-established findings—but it may also protect against developing Alzheimer’s disease, according to findings reported at the ...
Highlights From the 2021 ASH Annual Meeting & Exposition
The ongoing COVID-19 pandemic and successful hybrid format dominated much of the discussion at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, but the lasting impact of the meeting will be the groundbreaking research that was presented. Throughout all diseases,...
Meta-Analysis of Aromatase Inhibitors vs Tamoxifen in Premenopausal Women With ER-Positive Early-Stage Breast Cancer Receiving Ovarian Suppression
In a patient-level meta-analysis reported in The Lancet Oncology, researchers from the Early Breast Cancer Trialists’ Collaborative Group found that use of an aromatase inhibitor vs tamoxifen reduced the risk of recurrence in premenopausal women with estrogen receptor (ER)-positive early breast...
Tofacitinib for Rheumatoid Arthritis: Cancer and Cardiovascular Event Risks
In a phase IIIb/IV safety endpoint trial (ORAL Surveillance) reported in The New England Journal of Medicine, Ytterberg et al found that treatment with the JAK inhibitor tofacitinib for rheumatoid arthritis was associated with higher rates of cancer and major cardiovascular events compared with...
Web-Based Intervention to Manage Symptoms and Quality of Life in Women With Recurrent Ovarian Cancer
In an NRG Oncology/GOG study (GOG-0259) reported in the Journal of Clinical Oncology, Donovan et al found that both nurse-led (Nurse-WRITE) and self-directed (SD-WRITE) Web-based symptom self-management interventions (WRITE Symptoms) improved symptom control vs enhanced usual care alone in women...
Centralizing Care for Adolescents and Young Adults With Cancer to Improve Long-Term Survivorship
This past fall, Memorial Sloan Kettering (MSK) Cancer Center in New York expanded its adolescent and young adult (AYA) program with the establishment of the Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers. The Stuart Center is now part of the increasing list of about 50 academic ...
Studies Show That Laws to Limit Opioid Prescribing Have Hampered Pain Control for Patients With Cancer
In 2015, an unprecedented phenomenon occurred in the United States: according to the World Bank Group, the nation’s average life expectancy fell from 78.8 years in 2014 to 78.7 years in 2015, then to 78.5 years in 2017. The last time our life expectancy registered a similar decline was in the years ...
Does Daily Aspirin Help Prevent Breast Cancer Recurrence?
Taking aspirin daily does not prevent breast cancer recurrence, according to research presented by Wendy Y. Chen, MD, MPH, a medical oncologist at Dana-Farber Cancer Institute, during the February 2022 ASCO Plenary Series session (Abstract 360922). Results of a double-blind phase III study of more...
KRAS G12C Inhibitor Sotorasib Shows Activity in Certain Patients With Pancreatic Cancer
Sotorasib, an irreversible inhibitor of KRAS G12C, showed activity in patients with metastatic pancreatic cancer and a KRAS G21C mutation enrolled in the phase I/II CodeBreaK100 study. These findings were presented during the February 2022 ASCO Plenary Series session by John H. Strickler, MD,...
Report Documents Third Known Case of HIV Remission Involving Stem Cell Transplant
A woman with human immunodeficiency virus (HIV) who received a cord blood stem cell transplant to treat acute myeloid leukemia has had no detectable levels of HIV for 14 months, despite cessation of antiretroviral therapy, according to research presented at the Conference on Retroviruses and...
Niraparib in Previously Treated Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Repair Gene Defects
In the phase II GALAHAD trial reported in The Lancet Oncology, Matthew R. Smith, MD, and colleagues found that the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib showed activity in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects whose disease had...
Robert M. Califf, MD, MACC, Confirmed as FDA Commissioner
On February 15, the Senate voted 50 to 46 to confirm Robert M. Califf, MD, MACC, as Commissioner of the U.S. Food and Drug Administration (FDA). Dr. Califf was previously the Commissioner of the FDA from February 2016 to January 2017. He also served as the FDA’s Deputy Commissioner for Medical...
Differences in Risk of Severe Adverse Events in Women vs Men Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials
In a study reported in the Journal of Clinical Oncology, Joseph M. Unger, PhD, and colleagues found that women in clinical trials of chemotherapy, immunotherapy, or targeted therapy had a significantly greater risk for severe adverse events overall—and, particularly, with immunotherapy. As stated...
Potential Use of FDG-PET Findings in Reducing Duration of Immunotherapy in Patients With Advanced Melanoma
In a Danish retrospective study reported in the International Journal of Cancer, Ellebaek et al found that patients with advanced melanoma responding to PD-1 inhibitor therapy who stopped treatment within 18 months had improved survival outcomes when fluorodeoxyglucose (F-18) positron-emission...
Are Patients Undergoing Active Cancer Treatment More Likely to Believe COVID-19 Misinformation?
Patients with cancer undergoing active treatment were more likely to believe misinformation related to COVID-19 than those without a history of cancer, according to a new study published by Guidry et al in Patient Education and Counseling. “These findings help us better understand the threat of...
H1-Antihistamine Use and Risk of Hepatocellular Carcinoma in Persons With Hepatitis B Virus, Hepatitis C Virus, or Dual Infection
In a Taiwanese study reported in the Journal of Clinical Oncology, Shen et al found that use of H1-antihistamines was associated with reduced risk of hepatocellular carcinoma in patients with hepatitis B virus (HBV), hepatitis C virus (HCV), or dual HBV/HCV infection. Study Details The study...
Cemiplimab-rwlc vs Single-Agent Chemotherapy in Recurrent Cervical Cancer After First-Line Platinum-Based Chemotherapy
As reported in The New England Journal of Medicine by Krishnansu S. Tewari, MD, and colleagues, the phase III EMPOWER-Cervical1/GOG-3016/ENGOT-cx9 trial has shown improved overall survival with cemiplimab-rwlc vs investigator’s choice of single-agent chemotherapy in patients with cervical cancer...
Comprehensive Genetic Risk Score May Predict Risk of Developing Metastatic Prostate Cancer or Death From Prostate Cancer Across Diverse Populations
A new screening tool (called PHS290) that incorporates 290 inherited genetic variants associated with prostate cancer was able to accurately identify people with high vs low lifetime risks of developing metastatic prostate cancer or dying from prostate cancer. These findings of a genetic risk...
Updated Efficacy and Safety Data From CheckMate 743: First-Line Nivolumab/Ipilimumab vs Chemotherapy for Unresectable Malignant Pleural Mesothelioma
With a follow-up of at least 3 years, the results from the CheckMate 743 study represent the first long-term survival data in a phase III study evaluating first-line immune checkpoint inhibition in patients with unresectable malignant pleural mesothelioma. Overall, 23% of patients treated with...
Report Finds Cancer Immunotherapy Clinical Trials Continue to Grow Globally
The Cancer Research Institute (CRI), a nonprofit organization dedicated to the discovery and development of powerful immunotherapies for all types of cancer, has announced the publication of a new analysis of the global landscape of clinical development of drugs that target the PD-1/PD-L1 immune...
American Cancer Society Publishes Cancer Statistics for African American/Black People 2022
In a major shift, breast cancer has surpassed lung cancer as the leading cause of cancer death among Black women as of 2019. This news is one of the key findings in a new report from the American Cancer Society, Cancer Statistics for African American/Black People 2022, published by Giaquinto et al...
Ibrutinib/Rituximab Induction Followed by R-HCVAD in Front-Line Treatment of Patients Aged 65 and Younger With Mantle Cell Lymphoma
In the single-institution phase II WINDOW-1 trial reported in The Lancet Oncology, Michael L. Wang, MD, and colleagues found that 12 cycles of induction ibrutinib/rituximab produced objective response in nearly all patients aged ≤ 65 years with mantle cell lymphoma, allowing a reduction in cycles...
Neoadjuvant Atezolizumab Plus Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Funt et al found that the combination of neoadjuvant atezolizumab with gemcitabine and cisplatin resulted in a high rate of tumor downstaging to < pT2N0 in patients with muscle-invasive bladder cancer. Study Details The U.S....
Efficacy of Adagrasib in Various Gastrointestinal Cancers
In this episode, we’ll review a report on the KRYSTAL-1 trial of adagrasib therapy in various gastrointestinal cancers and highlight key points from the newly released AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care.
Importing Oncology Trials From China, or Other Single Foreign Countries, for Consideration of U.S. Regulatory Approvals
In a commentary published in The Lancet Oncology, Harpreet Singh, MD, and Richard Pazdur, MD, both of the Oncology Center of Excellence at the U.S. Food and Drug Administration (FDA), warned against the increasing number of oncology drug development programs based wholly or predominantly on data...
Sara A. Hurvitz, MD, on HER2-Positive Metastatic Breast Cancer: T-DXd vs T-DM1
Sara A. Hurvitz, MD, of the University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses phase III findings from the DESTINY-Breast03 trial, which compared ado-trastuzumab deruxtecan (T-DXd) with standard-of-care trastuzumab emtansine (T-DM1) in patients with HER2-positive...
Study Identifies Factors Impacting Adherence to Oral Medications for Metastatic Breast Cancer
A recent study published by Conley et al in Breast Cancer Research and Treatment aimed to evaluate factors that influence the ability of people with metastatic breast cancer to adhere to their prescribed regimen of oral anticancer medication. Researchers found that multiple factors affected...
